Tom Carroll

Co-Founder & CSO of Numen (@numenbio, YC S23) • Rice/Oxford Alum • Rhodes Scholar (Texas & Magdalen, 2016) • zipper club (Indiana & BAV, 2019)

[Luca Springer @luca_springer]

Building @numenbio with @_tom_dot_com to engineer a future without cancer deaths. Find out more below in an interview with our partners at @TQVentures!

[Tom Carroll @_tom_dot_com]

Proud to be building @numenbio with @luca_springer and with great backers like @TQVentures in our corner!

[TQ Ventures @TQVentures]

A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container.

What it actually takes to build it:

“If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.”

@luca_springer, co-founder and CEO of @numenbio

Timestamps:
00:00 Welcome to Numen
00:56 Why catch cancer early
01:24 The first lab was a shipping container
02:28 What the data unlocks next
03:23 National team MVP to founder
04:13 Why bladder cancer first
05:33 The candle prototype
06:25 Meet Atlas, a lab in a cup
06:55 NASA engineers under one roof
07:32 The Viennese café
08:08 Pipette pong
08:46 From the dungeon to Golden Gate Park
09:28 The only milestone that matters
09:59 40 years on one problem

[TQ Ventures @TQVentures]

A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container.

What it actually takes to build it:

“If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.”

@luca_springer, co-founder and CEO of @numenbio

Timestamps:
00:00 Welcome to Numen
00:56 Why catch cancer early
01:24 The first lab was a shipping container
02:28 What the data unlocks next
03:23 National team MVP to founder
04:13 Why bladder cancer first
05:33 The candle prototype
06:25 Meet Atlas, a lab in a cup
06:55 NASA engineers under one roof
07:32 The Viennese café
08:08 Pipette pong
08:46 From the dungeon to Golden Gate Park
09:28 The only milestone that matters
09:59 40 years on one problem

[Numen @numenbio]

We’ve been building quietly at @numenbio for the past few years. Tomorrow we’re sharing more for the first time, in a conversation with Schuster at @TQVentures.

Here’s a teaser; full interview tomorrow.

[Tom Carroll @_tom_dot_com]

Operable setting (2026): https://t.co/1JIgHkcUer
Inoperable setting (2023): https://t.co/BdzYAYtCFP

In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!

[Tom Carroll @_tom_dot_com]

🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:

[Tom Carroll @_tom_dot_com]

Operable setting (2026): https://t.co/1JIgHkcUer
Inoperable setting (2023): https://t.co/BdzYAYtCFP

In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!

[Tom Carroll @_tom_dot_com]

🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:

[Debesh Mandal @debesh]

The reason mRNA can't cure more diseases? Delivery.

We built NGX1 to deliver mRNA to any cell in the body using AI and multivalent physics.

[NEJM @NEJM]

Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: https://t.co/5Y1ZnAvBFK

Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? https://t.co/Jkuc0w9hhV

[Tom Carroll @_tom_dot_com]

@SirenBio @CIRMnews Congrats!

[Jordan Bloom @JordanBloomMD]

Truly monumental day for the #Ross community. Congratulations to trailblazers and colleagues @IHamamsy and @OuzounianMD for simultaneous publication of their incredible manuscripts reaffirming the magic of the Ross Procedure in @JACCJournals

[Anirban Maitra @Aiims1742]

🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!

AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O

[Tom Carroll @_tom_dot_com]

Follow me to see if the vibe-folded brackets can bring home first place, and for more on what else we can do with these models 😎

[Tom Carroll @_tom_dot_com]

So how good are these predictions? Mercifully, this strat only picked 3/8 possible 16 seed upsets. Through Day 1 of the men’s bracket, we're not too shabby! Picked some key upsets from #12 High Point, #11 Texas, and #11 VCU. Must be some bball training data somewhere in UniRef.

[Sketching Science @sketchscience]

For the second year in a row, Parafilm has been recognized with the Nobel Prize in Chemistry 2025! 🏅

[McNeil @REFLOG18]

This team 😂😂